Estefanía Sicco

Dr. Estefanía Sicco


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2017 in Blood
Verified
Journal Article
Closed access
PDF file
DPDaniel Prieto
Daniel Prieto
NSNatalia Sotelo
Natalia Sotelo
NSNoé Seija
Noé Seija
SSSandra Sernbo
Sandra Sernbo
CACecilia Abreu
Cecilia Abreu
POPablo Oppezzo
Pablo Oppezzo
Key Points: Plasma-derived exosomes from patients with CLL exhibit different protein cargo compositions depending on disease status and progression. S100-A9 protein is overexpressed and S100-A9 cargo in exosomes activates NF-κB pathway in patients with CLL during disease progression.

20 July 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
VPVanesa Pereira-Prado
Vanesa Pereira-Prado
FMFelipe Martins-Silveira
Felipe Martins-Silveira
ESEstefanía Sicco
Estefanía Sicco
JHJimena Hochmann
Jimena Hochmann
Mario Alberto Isiordia-EspinozaMario Alberto Isiordia-Espinoza
Mario Alberto Isiordia-Espinoza
Ronell Bologna-MolinaRonell Bologna-Molina
Ronell Bologna-Molina
Head and neck tumor differential diagnosis and prognosis have always been a challenge for oral pathologists due to their similarities and complexity. Artificial intelligence novel applications can function as an auxiliary tool for the objective interpretation of histomorphological digital slides. In this review, we present digital histopathological image analysis applications in oral squamous cell carcinoma. A literature search was performed in PubMed MEDLINE with the following keywords: “artificial intelligence” OR “deep learning” OR “machine learning” AND “oral squamous cell carcinoma”. Artificial intelligence has proven to be a helpful tool in histopathological image analysis of tumors and other lesions, even though it is necessary to continue researching in this area, mainly for clinical validation.

1 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ESEstefanía Sicco
Estefanía Sicco
HCHugo Cerecetto
Hugo Cerecetto
VCVictoria Calzada
Victoria Calzada
MMMaría Moreno
María Moreno
Aptamers are emerging as a promising new class of functional nucleic acids because they can specifically bind to any target with high affinity and be easily modified chemically with different pharmacophoric subunits for therapy. The truncated aptamer, Sgc8-c, binds to tyrosine-protein kinase-like 7 receptor, a promising cancer therapeutic target, allowing the recognition of haemato-oncological malignancies, among others. We have previously developed aptamer-drug conjugates by chemical synthesis, hybridizing Sgc8-c and dasatinib, a drug proposed for lymphoma chemotherapy. One of the best-characterised Sgc8-c-dasatinib hybrids, namely Sgc8-c-carb-da, was capable of releasing dasatinib at an endosomal-pH. Herein, we probed the therapeutic potential of this aptamer-drug conjugate. Sgc8-c-carb-da specifically inhibited murine A20 B lymphocyte growth and produced cell death, mainly by late apoptosis and necrosis. In addition, Sgc8-c-carb-da generated an arrest in cell proliferation, with a cell cycle arrest in the Sub-G1-peak. The mitochondrial potential was altered accordingly to these pathways. Moreover, using an in vitro cell-targeting assay that mimics in vivo conditions, we showed that Sgc8-c-carb-da displayed higher (2.5-fold) cytotoxic effects than dasatinib. These findings provide proof-of-concept of the therapeutic value of Sgc8-c-carb-da for lymphoma, creating new opportunities for the chemical synthesis of targeted biotherapeutics.

24 November 2017 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
ESEstefanía Sicco
Estefanía Sicco
Jessica BáezJessica Báez
Jessica Báez
JMJimena Margenat
Jimena Margenat
FGFernanda García
Fernanda García
Manuel IbarraManuel Ibarra
Manuel Ibarra
VCVictoria Calzada
Victoria Calzada

30 May 2018 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
DADelmira Apellániz
Delmira Apellániz
VPVanesa Pereira-Prado
Vanesa Pereira-Prado
ESEstefanía Sicco
Estefanía Sicco
GVGabriela Vigil-Bastitta
Gabriela Vigil-Bastitta
Rogelio González-GonzálezRogelio González-González
Rogelio González-González
Ronell Bologna-MolinaRonell Bologna-Molina
Ronell Bologna-Molina
Introduction. Solid/conventional ameloblastoma (AM) and unicystic ameloblastoma (UAM) are the most frequent benign epithelial odontogenic tumors located in the maxillary region, and their treatment usually consists of extensive surgical resection. Therefore, it is relevant to study molecular markers to better understand the biological behavior of these tumors. The aim of this study was to describe and compare the expression of proteins related to cellular proliferation: Ki-67 and MCM4-6 complex. Materials and Methods. An immunohistochemistry technique was performed, with antibodies against Ki-67, MCM4, MCM5, and MCM6, in 10 AM and 10 UAM tumors. The results were quantified using label index and analyzed statistically. Results. AM and UAM had greater expression of MCM6, followed by MCM5, MCM4, and Ki-67 (P < .05). Immunoexpression of Ki-67 and MCM5 was exclusively nuclear, whereas the expression of MCM4 and MCM6 was nuclear and cytoplasmic. Conclusion. The results suggest that MCM5 is a trustable cell proliferation marker with higher sensitivity compared with Ki-67 and may be useful to predict the biological behavior of AM and UAM. Despite this, further studies are necessary, including a correlation with clinical parameters to confirm these findings.

15 October 2024 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
LPLucas Fabián Polti
Lucas Fabián Polti
ESEstefanía Sicco
Estefanía Sicco
FMFelipe Martins-Silveira
Felipe Martins-Silveira
LGLuis Giovacchini
Luis Giovacchini
PGPablo Giovacchini
Pablo Giovacchini
MPMaría Luisa Paparella
María Luisa Paparella